Back to Search Start Over

Genetic diagnosis and clinical analysis of 17α-hydroxylase/17, 20-lyase deficiency combined with type 2 diabetes mellitus: A case report.

Authors :
Zhang Y
Yuan Y
Source :
Medicine [Medicine (Baltimore)] 2023 Dec 29; Vol. 102 (52), pp. e36727.
Publication Year :
2023

Abstract

Rationale: 17α-Hydroxylase/17, 20-lyase deficiency (17OHD) is a recessively inherited autosomal disease caused by CYP17A1 gene mutations. It is characterized by failure to synthesize cortisol, adrenal androgens and gonadal steroids. However, it is rare in clinic combining with type 2 diabetes mellitus (T2DM).<br />Patient Concerns: A 21-year-old woman was transferred to an endocrinology clinic because of paroxysmal paralysis. In addition, she presented with hypertension, primary amenorrhea and lack of pubertal development. Blood evaluation revealed hypokalemia, and a low cortisol level with an increased adrenocorticotropic hormone concentration. The renin activity and testosterone and estrogen levels were suppressed, and the gonadotropin levels were high. CT scan showed bilateral adrenal hyperplasia. Besides, this patient had hyperglycemia, hyperinsulinism and negative diabetes type 1 related antibodies. A homozygous mutation c. 985 to 987delinsAA in exon 6 was found in the patient which caused the missense mutation (p.Y329fs).<br />Diagnoses: 17α-hydroxylase/17, 20-lyase deficiency combined with T2DM was considered.<br />Interventions: The patient received dexamethasone, estradiol valerate, metformin, amlodipine besylate and D3 calcium carbonate tablets. The doses of dexamethasone was changed according to her blood potassium levels.<br />Outcomes: After treatment, the blood pressure, blood potassium and blood glucose returned to normal range. Besides, she had restored her menstrual cycle.<br />Lessons: For patients with hypertension, hypokalemia and lack of pubertal development, the possibility of 17OHD should be considered. The subsequent treatment would be challenging in patients with combined 17OHD and T2DM, considering the potential contribution of glucocorticoids to diabetic balance and osteoporosis.<br />Competing Interests: The authors have no conflicts of interest to disclose.<br /> (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)

Details

Language :
English
ISSN :
1536-5964
Volume :
102
Issue :
52
Database :
MEDLINE
Journal :
Medicine
Publication Type :
Academic Journal
Accession number :
38206738
Full Text :
https://doi.org/10.1097/MD.0000000000036727